ArticleThe journal of pathology. Clinical research2016
Novel translational model of resolving inflammation triggered by UV-killed E. coli.
Article in The journal of pathology. Clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- In vivo human keyhole limpet hemocyanin challenge in early phase drug development: A systematic review.Clinical and translational science · 2023Pooled it
- Early immune responses to intradermal lipopolysaccharide in healthy volunteers: prednisolone's impact on TLR4-mediated inflammation.Frontiers in immunology · 2026Trial
- Profiling a Neo-Antigen-Driven Immune Response in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Study of the KLH Challenge Model.Clinical pharmacology and therapeutics · 2025Trial
- Immunomodulating effects of the single bacterial strain therapy EDP1815 on innate and adaptive immune challenge responses - a randomized, placebo-controlled clinical trial.Immunologic research · 2024Trial
- The oral IRAK4 inhibitors zabedosertib and BAY1830839 suppress local and systemic immune responses in a randomized trial in healthy male volunteers.Clinical and translational science · 2024Trial
- Potent Anti-Inflammatory and Pro-Resolving Effects of Anabasum in a Human Model of Self-Resolving Acute Inflammation.Clinical pharmacology and therapeutics · 2018Trial
- Epoxy-oxylipins direct monocyte fate in inflammatory resolution in humans.Nature communications · 2026Article
- A new model measuring bacterial phagocytosis and phagolysosomal oxidation in humans using the intradermal injection of methylene blue-labeled Escherichia coli.Journal of leukocyte biology · 2025Article
- Prenatal Stress Increases the Risk of the FPR2-related Dysfunction in the Brain's Resolution of Inflammation: A Study on the Humanized APPCurrent neuropharmacology · 2025Article
- Challenges of monocyte HLA-DR targeted immunomodulation in sepsis-a prospective observational cohort study.Frontiers in immunology · 2025Observational
- Efferocytosis: a therapeutic strategy for diabetes and its vascular complications.Frontiers in cell and developmental biology · 2025Review
- The translational potential of inflammation-induced skin blister human models in exploring the pathogenesis of periodontitis and its systemic health implications.Frontiers in immunology · 2024Review
- Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers.Clinical pharmacology and therapeutics · 2022Article
- A novel Streptococcus pneumoniae human challenge model demonstrates Treg lymphocyte recruitment to the infection site.Scientific reports · 2022Article
- Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers.British journal of clinical pharmacology · 2022Article
- Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function.Nature reviews. Nephrology · 2021Review
- Monocytes, macrophages, dendritic cells and neutrophils: an update on lifespan kinetics in health and disease.Immunology · 2021Review
- UV radiation recruits CD4Clinical & translational immunology · 2020Article
- Ajulemic acid: potential treatment for chronic inflammation.Pharmacology research & perspectives · 2018Review
- Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli-driven acute inflammation.JCI insight · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Whilst numerous studies investigating the aetiology of inflammatory diseases have been performed in rodents, the applicability of these data to human pathophysiology is frequently debated. Regardless of the strengths and weaknesses of rodent models in biomedical research, there is a need to develop models of experimental inflammation in humans. Here, we describe a self-resolving acute inflammatory response triggered by the intradermal injection of UV-killed Escherichia coli into the forearm of healthy volunteers. Cells and exudates were harvested from onset to resolution by applying negative pressure over the inflamed site. Onset was characterized by high blood flow, neutrophilia and peak levels of pro-inflammatory cytokines, whilst resolution showed a decline in blood blow, reduction in neutrophils, increase in monocytes/macrophages and waning of classic pro-inflammatory cytokine levels. An anti-inflammatory effect, defined as suppression of onset phase events, was demonstrated by administering naproxen, a conventional non-steroidal anti-inflammatory drug. In summary, this model of resolving acute inflammation is minimally invasive, highly tractable and allows simultaneous investigation of the vascular response, cellular trafficking and chemical mediator profile of onset and resolution phases of acute inflammation in humans. It can serve as a translational platform to provide mechanistic insights and to test the clinical efficacy of novel anti-inflammatory and pro-resolving drugs, and also as a tool in patients to explore inherent defects in resolution pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.